Gabapentin Capsule
Product Images NDC 70518-1834

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-1834). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Gabapentin 100 mg capsules label showing the quantity of 30 capsules. The label includes the NDC number 70518-1834-00, manufacturing by Ascend Labs, LLC in Montvale, NJ, and repackaging information by RemedyRepack Inc., Indiana, PA. Directions reference the package insert, with storage instructions between 20-25°C. The label states 'RX ONLY'.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula calculation panel illustrating creatinine clearance (CLCr) which involves age, weight, serum creatinine, and a factor adjustment for female patients. The image presents a mathematical equation used in clinical settings for estimating kidney function.*

FDA Label Image

Gabapentin Fig1

A line graph comparing mean pain scores over 8 weeks between placebo and Gabapentin at 3600 mg/day. The x-axis shows weeks from baseline to 8, divided into a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10, with Gabapentin consistently showing lower pain scores than placebo.*

FDA Label Image

Gabapentin Fig2

A line graph depicting mean pain scores over 7 weeks comparing placebo and gabapentin dosages (1800 mg/day and 2400 mg/day). The x-axis represents weeks, divided into a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10, illustrating decreases in pain scores for gabapentin groups compared to placebo over time.*

FDA Label Image

Gabapentin Fig3

Bar chart showing the proportion of responders (patients with ≥ 50% reduction in pain score) at endpoint in two controlled PHN studies. Study 1 compares placebo (PBO) at 12% to Gabapentin (GBP) 3600 mg at 29%. Study 2 compares placebo at 14% to GBP 1800 mg at 32% and GBP 2400 mg at 34%. Statistical significance markers indicate p-values less than 0.01 and 0.001 for some comparisons.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot chart depicting the percent difference on the vertical axis and daily dose in milligrams on the horizontal axis. The chart compares results from three different studies labeled a, b, and c, showing dose-dependent differences at 600 mg, 900 mg, 1200 mg, and 1800 mg daily doses of gabapentin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.